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Abstract
Background: Conventionally, human monocyte sub-populations are classified according to surface marker expression
into classical (CD14++CD16−), intermediate (CD14++CD16+) and non-classical (CD14+CD16++) lineages. The involvement
of non-classical monocytes, also referred to as proinflammatory monocytes, in the pathophysiology of diseases including
diabetes mellitus, atherosclerosis or Alzheimer’s disease is well recognized. The development of novel high-throughput
methods to capture functional states within the different monocyte lineages at the whole cell proteomic level will
enable real time monitoring of disease states.
Results: We isolated and characterized (pan-) monocytes, mostly composed of classical CD16− monocytes, versus
autologous CD16+ subpopulations from the blood of healthy human donors (n = 8) and compared their inflammatory
properties in response to lipopolysaccharides and M.tuberculosis antigens by multiplex cytokine profiling. Following
resting and in vitro antigenic stimulation, cells were recovered and subjected to whole-cell mass spectrometry analysis.
This approach identified the specific presence/absence of m/z peaks and therefore potential biomarkers that can
discriminate pan-monocytes from their CD16 counterparts. Furthermore, we found that semi-quantitative data
analysis could capture the subtle proteome changes occurring upon microbial stimulation that differentiate resting,
from lipopolysaccharides or M. tuberculosis stimulated monocytic samples.
Conclusions: Whole-cell mass spectrometry fingerprinting could efficiently distinguish monocytic sub-populations that
arose from a same hematopoietic lineage. We also demonstrate for the first time that mass spectrometry signatures can
monitor semi-quantitatively specific activation status in response to exogenous stimulation. As such, this approach stands
as a fast and efficient method for the applied immunology field to assess the reactivity of potentially any immune cell
types that may sustain health or promote related inflammatory diseases.
Keywords: Whole-cell mass spectrometry, MALDIquant, Fingerprints, Monocyte, CD14, CD16, MDC8
Background
Five to 15% of human blood mononuclear cells are
monocytes. Upon extravasation into inflamed tissue, their
ability to differentiate into monocyte-derived macrophages
and dendritic cells make them key components of the
innate immune system to initiate adaptive immune
responses and contribute to tissue homeostasis upon
resolution of inflammation [1]. Based on the most recent
nomenclature, monocytes can be divided into classical
(CD14++CD16−), intermediate CD14++CD16+ and non-
classical (CD14+CD16++) short-lived cells which are
constantly replenished from a common myeloid progeni-
tor [2-4]. Their phenotypic characterization is usually
performed by flow cytometry using a gating strategy
in combination with HLA-DR labelling to exclude the
measurement of NK cells and granulocytes expressing
the CD16 marker as well [5].
Based on their CD16 expression levels, monocyte
subpopulations have different chemotactic, phagocytic
and inflammatory abilities [6] and distinct propensities to
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differentiate into professional antigen presenting cells [7].
In fact, blood monocyte composition is heterogeneous
between human individuals and gender [8] and within
individuals it can be substantially altered by infections
such as septicaemia, HIV and M. tuberculosis infection
[9-11] during which the CD16+ compartment can increase
dramatically. In the case of M. tuberculosis infection, a
functional deficiency in the CD16+ subset to recall specific
immune responses due to an impaired dendritic cell
differentiation has been notably described [12]. In
contrast, a human genetic trait associated to an absent
CD16+ compartment in the blood was not necessarily
associated with disease [13]. Nevertheless, these inherent
and induced discrepancies between humans have led to a
series of reports describing association of the blood
monocyte composition and recruitment with a particular
emphasis on CD16+ monocytes in the pathogenesis of
non-communicable inflammatory disorders such as
atherosclerosis [14], stroke [15], rheumatoid arthritis
[16] and diabetes complications [17] but also Alzheimer’s
disease [18], and experimental models of human disorder
multiple sclerosis [19], tumour genesis and metastasis
[20]. In that context, we aimed to develop a method
that could assess CD16+ monocyte functionalities for
the diagnosis/prognosis but also severity or resolution
monitoring of those diseases which may be particu-
larly meaningful in the context of immune-based
therapeutics targeting the recruitment of monocytes
[21].
Untargeted mass spectrometry analysis of complex
samples such as entire prokaryotic or eukaryotic cell
lysates that are directly spotted in the MALDI ionisation/
desorption matrix offers a fast method for rapid iden-
tification of bacteria [22] but also the discrimination/
authentication of mammalian and insect cell lines
[23-26]. This approach notably prevents any potential
bias or reproducibility issues due to purification or
fractionation steps prior mass spectrometry analysis.
Whole-cell MALDI-TOF “fingerprints” or “signatures”
performed on human primary blood cells were shown
to reproducibly discriminate lymphocytes from monocytes
or granulocytes or between macrophage subtypes with
relatively low starting material ranging between 25 × 102
to 5 × 104 cells [27,28]. In that context, we aimed to assess
whether whole-cell MALDI-TOF fingerprinting would
have enough discriminatory power to i) distinguish human
monocyte subpopulations and ii) monitor activation
profiles of monocytes exposed to distinct microbial
ligand. We purified monocytes from healthy individuals
(n = 8) and isolated autologous CD16+ subpopulations.
Cell preparations were immunologically characterized
and following stimulation with LPS and M. tuberculosis
derived antigens subjected to MALDI-TOF analysis. We
extracted semi-quantitative mass spectrometry data to
highlight monocytic subset discriminatory biomarkers as
well as specific microbial activation profiles.
Methods
Ethics statement
Fresh blood packs (buffy coat) were purchased anonym-
ously from the Blutspendezentrum SRK beider Basel,
Switzerland. In compliance with the Helsinki Declar-
ation, signed informed consents stating specifically
that “the donation or certain components thereof be
used for medical research after definitive anony-
mization” was obtained prior blood donation. Consent
form was accessed on October 31st 2014 and can be
found here: http://blutspende-basel.ch/fileadmin/BSZ/docs/
blutspende/2015_Blutspendeaufgebot_en.pdf. An ethics
board approval for this study was consequently not
required.
Blood processing and monocyte isolation
Peripheral Blood Mononuclear Cells (PBMCs) were
immediately isolated by density centrifugation using
pre-filled Greiner Bio-One Leucosep® tubes according
to the manufacturer’s recommendations. PBMCs rings
were collected and washed twice in PBS before final
suspension at 20 × 106 cells/ml in ice-cold freezing
medium (50% RPMI-1640, 40% fetal bovine serum,
10% DMSO) and transferred at −80°C in Nalgene® Mr.
Frosty for short-term storage (<1 month). For monocyte
isolation, 40 × 106 to 60 × 106 cells of cryopreserved
PBMCs were thawed and quickly washed with 13 ml
ice-cold RPMI-1640. Median cell viability upon recovery
was assessed by trypan blue exclusion (88.37%, IQR:
82.1-97). Pan- and CD16+ monocyte purification were
performed using Pan Monocyte Isolation Kit and
CD16+ Monocyte Isolation Kit respectively according to
manufacturer’s instructions (Miltenyi Biotec GmbH).
Flow cytometry analysis
Prior final washing steps, 100 μl suspension of PBMCs,
pan-monocytes and CD16 monocytes were spared and
washed with PBS 1% FCS before antibody staining for
15 min on ice with anti-CD14 FITC (MΦP9, Becton
Dickinson), anti-CD16-PE (Leu11c, Becton Dickinson)
and anti-Slan (MDC8, Miltenyi Biotec). After washing,
antibody labelled cell preparation were immediately ana-
lysed on a BD FACSCalibur apparatus (BD Biosciences)
and data analyzed using FlowJo 9.5.2 (Treestar).
Cell culture conditions
Monocyte suspensions were cultivated in 96-well
flat-bottom tissue culture treated plates at a density of 2 ×
105 cells per well in complete medium (RPMI-1640
(Gibco Life Technologies™) complemented with 5% heat-
inactivated fetal bovine serum (PAA Laboratories GmbH),
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100 mM Na-pyruvate (Gibco), Penicillin/Streptomycin
(50 U & 50 μg/ml respectively, Gibco) for 24 hours
at 37°C in a humidified atmosphere with 5% CO2 in
the presence or absence (resting) of PPD (RT50, Statens
Serum Institute, 5 μg/ml final) or LPS (O111:B4, 10 ng/ml
final, Sigma-Aldrich). After 24 hours of resting/incubation
period, tissue culture plates were placed on ice for
15 minutes and the cells re-suspended by vigorous
pipetting, pelleted by centrifugation (250 RCF) and
cell pellets transferred at −80°C.
Cytokine profiling
Cytokine concentrations present in monocyte culture
supernatants were measured using Bio-Plex Pro™ Human
Cytokine Group I kit according to manufacturer’s instruc-
tions and data acquired on a Luminex® 200™ System.
Whole-cell mass spectrometry
Cryopreserved cell pellets were washed with 70% ethanol
and briefly vortexed before centrifugation (10 min,
16000 RCF). Supernatants were discarded, cell pellets
dried for 1 minute at room temperature and finally
solubilized with 10 μl formic acid 10%, mixed with 2
volumes of a saturated sinapinic acid solution (40 mg
for 1 ml of acetonitrile 60%/H20 37%/TFA 3%) and
spotted in quadruplicates on a MALDI-TOF chip. External
calibration was performed using ribosomal corresponding
m/z signals from whole-cell E. Coli (DH5α). Mass spectra
(m/z mass range: 3000 to 30000) were acquired on a
Shimadzu Biotech Axima Confidence.
Quantitative analysis of mass spectrometry data using
MALDIquant R package
Mass spectra were pre-aligned to conserved m/z peaks
at 4078.8 and 14019.1, exported as mzXML files using
MALDI-MS Shimadzu Biotech Launchpad 2.8.1 (Kratos
Analytical Ltd) and imported using R Studio version
0.98.945 and MALDIquant Foreign R package. Using
MALDIquant package [29], mass spectra were square-root
transformed, smoothed using Savitz-Golay-Filter, baseline
corrected using TopHat method and intensity values
median-normalized so as to set to one the median of peak
intensities of each mass spectrum individually before
alignment using the Lowess warping algorithm. Peak
detection was performed using a signal-to-noise ratio
of 3. Peak list and their respective intensities were retrieved
and peak intensities obtained from each quadruplicates
averaged using OpenOfficeCalc before further statistical
analysis.
Statistical analysis
Wilcoxon signed rank tests, two-way ANOVA with
Bonferroni post-test corrections were performed and
scatter-plots generated using GraphPad prism (version
4.03, San Diego, CA, USA). Principal component ana-
lyses using correlation matrix were conducted using
Paleontological Statistics Software package for education
and data analysis, version 2.17c [30].
Results and discussion
Phenotypic and functional characterization of Pan- versus
autologous CD16+ monocytes
Cryo-preserved PBMCs from adult healthy donors (n = 8)
were thawed and used to enrich for pan-monocyte and
CD16+ monocyte sub-populations. Purified cell populations
were analysed by flow cytometry using antibodies directed
against the LPS receptor (CD14), the Fc-gamma receptor
III, CD16 and the P-selectin glycoprotein ligand-1
(Figure 1A). Flow cytometry data were subjected to
Boolean gating analysis to evaluate the representation
of individual sub-populations expressing one or several of
these cell surface markers. The majority of the pan-
monocyte cells expressed exclusively CD14 and no CD16
or MDC8 ligand (CD14+/CD16−/MDC8−) (Figure 1B).
Enriched CD16+ monocytes preparations could be divided
into three subpopulations expressing CD16 and/or
CD14 in combination with MDC8 ligand (Figure 1B).
MDC8 labelling was consistently associated with CD16
expression as described elsewhere [31]. The purity of the
pan- and CD16+ monocyte preparations were calculated
as 92.7% (IQR: 84–94.2) and 95.02% (IQR: 84.2-95.4),
respectively.
Non-classical or proinflammatory monocytes produce
high levels of TNF-α and low concentrations of IL-10 in
response to LPS stimulation [32]. We exposed the enriched
monocyte preparations to LPS or M. tuberculosis derived
purified protein derivative (PPD) for 24 h prior harvesting
of supernatants and assessment of cytokine and chemokine
production (Figure 2). In agreement with published results,
CD16+ monocyte preparations released significantly more
TNF-α after LPS and PPD stimulation and less IL-10 in
the context of LPS stimulation when compared to
pan-monocytes preparations consisting largely of
CD14+/CD16− classical monocytes. Similarly, we observed
an increased production of Mip1β by CD16+ monocytes
after PPD stimulation. No differences between pan- and
CD16+ monocyte preparations in their ability to secrete
other inflammatory mediators such as IL-6 or IL-1β after
LPS and PPD stimulation was observed (data not shown).
The secretion of MCP-1 (CCL2) by CD16+ monocytes
was significantly lower in comparison to autologous
pan-monocytes after LPS stimulation (Figure 2). This
is in contrast with the observation that CD16+ but
not CD16− monocytes secrete MCP-1 in response to
fractalkine (CX3CL1) receptor ligation [33]. Taken together
and since only CD16− circulating monocytes expresses
CCR2, the MCP-1 sensor [34], this suggests that while
patrolling tissues via CX3CL1-expressing endothelial cells,
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Figure 2 Cytokine and chemokine secretion of pan-monocytes and pro-inflammatory monocytes upon LPS and PPD stimulation. Pan-monocytes
(circles) and pro-inflammatory monocyte populations (squares) were subjected to LPS (grey) or M. tuberculosis PPD (black) stimulation for 24 h.
Supernatants were harvested and analysed for IL-10, MCP-1, MIP-1β and TNF-α levels (ND: not detectable). Data presented as scatter-plots were
subjected to Wilcoxon signed rank testing: *p < 0.05, **p < 0.01, *** p < 0.001.
Figure 1 Phenotypic characterization of isolated monocyte populations. Representative FACS-plot and scatter-plot frequencies of
A) Pan-monocytes and B) CD16+ monocytes based on the expression of CD14 versus CD16 (left plots) and CD16 versus P-selectin glycoprotein
ligand-1 (MDC8 antibody specificity [31], right plots). Scatter-plots summarizing frequencies of each sub-population based on the combinations
between the three monocytic markers are shown across all monocytes preparations (n = 8 healthy donors).
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CD16+ can contribute to classical monocyte recruitment
through MCP-1 production. However, under PPD stimula-
tion the enhanced secretion of Mip1β which receptor
(CCR5) is preferentially expressed by CD16+ circulating
monocytes suggests that once encountering M. tuberculosis
infectious foci, CD16+ monocytes may only recruit them-
selves. This interpretation is perfectly consistent with the
observation that CD16+ monocytes constitute the major
monocytic subset infiltrating tuberculous pleural fluid [11].
Quantitative whole-cell MALDI-TOF MS distinguishes
major monocyte subpopulations and captures immune
activation events
Next, we subjected the frozen monocyte cell preparations
to whole-cell Matrix Assisted Laser Desorption and
Ionization (MALDI) -TOF mass spectrometry analysis.
Briefly, cell pellets were lysed, spotted, analysed in
quadruplicates. MALDI lacks absolute quantitative
power per se. The presence of particular molecular
entities may suppress the detection of others for instance.
Furthermore, different molecular species have very unequal
abilities for desorption and ionisation. Nevertheless,
molecular species differing solely from a post-translational
modification are likely to behave similarly. Consequently
when comparing crude extracts from identical cells
cultivated in different conditions, we can assume that
variation in intensities or intensity ratios may attest
post-translational events or modification of the proteome
being analysed. In order to define ratios between different
molecular species within and ultimately between different
mass spectra, we performed a normalization step so as to
set the median intensities of all the peaks detected within
one spectrum to one (Figure 3). Mass spectra data
were extracted individually to evaluate semi-quantitatively
the intensity of m/z peaks with a signal to noise ratio >3
(353 peaks retained). Respective intensities were averaged
across technical quadruplicates for statistical analysis.
Raw data (e.g. m/z peak list and respective normalized
intensities) are presented as Additional file 1. The peak
intensity matrix was used for principal component ana-
lysis to visualize if individual monocyte preparations with
their different stimulation conditions can be separated
using whole-cell MALDI-TOFMS. As shown in Figure 4A,
PCA component 1 (with 43.4% of the variance) separated
unequivocally the pan- from the CD16+-monocytes.
Interestingly, although pan-monocytes preparations
contained a small proportion of CD16+ monocytes,
our mass spectrometry fingerprinting method identified
unambiguously biomarkers from the most abundant cell
population. The analyte suppression effect (ASE) [35] or
the competition between analytes for ionisation is
well acknowledged in MALDI-TOF MS. Ionisation of
molecules present in low concentrations is outcompeted
by the more abundant ones. We extended the PCA
analysis to the m/z peak list intensities specific to the
individual pan-monocyte preparations (Figure 4B).
Resting pan-monocytes segregated from LPS and PPD
stimulated samples whereas the two latter sample groups
showed some overlap with each other (Figure 4B). Resting
and stimulated CD16+ monocytes segregated unequivocally
from each other (Figure 4C).
Whole-cell MALDI-TOF MS captures molecular patterns of
cellular activation specific to monocyte subpopulations.
We subjected the m/z peak intensity list collected to a
two-way ANOVA statistical analysis with Bonferroni
post-test correction to extract m/z peaks significantly
over-represented in the two distinct resting monocyte
preparations (pooled data from 7 volunteers). A collection
of 25 unique m/z peaks that were significantly associated
with either of the pan-monocytes or CD16+-monocyte
preparations was obtained. In Figure 5, the mass spectra
area is given to depict the peaks with the highest expres-
sion fold-change (>2) between the two monocyte subpopu-
lations (pan-monocyte markers: m/z 9296.1, 10.24 average
fold-change, p < 0.001 and CD16+ marker: m/z 9720.3, 2.6
Figure 3 Representative mass spectrum prior and after processing with MALDIquant. A representative mass spectrum from pan-human monocytes
prior processing (A) and following square-root transformation, smoothing, baseline correction, intensity calibration and spectra alignment is depicted
in panel B. Blue crosses indicates significant peaks from the peak list obtained after filtering and provided as Additional file 1.
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average fold-change, p < 0.001). One would expect
that human genetic diversity should lead to quite sub-
stantial variability in the mass spectrometry profiles
of independent donors. The fact that the relative limited
amount of anonymous donors used in this study sufficed
to generate significant statistical differences speaks for the
robustness of the detected signals. Detection of those
masses alone or in combination with other hits could be
used as biomarkers for the specific qualitative assessment
of the respective monocyte subpopulations.
LPS signals through CD14 via the TLR4-MD-2 pathway
[36] whereas PPD triggers the MAPK (ERK1/2/P38) path-
way mostly via TLR2 signalling [37]. We next investigated
whether whole cell MALDI-TOF MS may offer unbiased
insights into immune activation events of monocytes
across those two distinct pathways. A two-way ANOVA
statistical analysis highlighted respectively 10 and 11 m/z
peaks differentially expressed by the pan- and the CD16+
monocyte preparations stimulated with LPS or PPD
(Figure 6A and B). Three m/z peaks (i.e. 10100.8,
11316.2 and 11396.3) overlapped between pan- and
CD16+ monocytes exposed to the two stimuli but their
respective pattern behaved remarkably differently. M/z
10100.8 was significantly induced in pan-monocytes
exposed to LPS while staying almost unchanged in
CD16+ monocytes under the same condition but in turn
significantly increased under PPD stimulation conditions.
Interestingly, m/z 11316.2 and 11396.3 differ from exactly
80 Da suggesting a potential post-translational modifica-
tions e.g. sulfation or phosphorylation [38]. The likelihood
of the latter is sustained by the various kinase activities in
cell signalling naturally associated to microbial stimula-
tions. Consistent with this hypothesis, we could observe a
significant decrease of the precursor at m/z 11316.2 while
Figure 4 Quantitative whole-cell MALDI-TOF MS discriminates resting and stimulated human monocyte subpopulations. Principal component
analysis of all samples combined (A); stimulated and resting pan-monocytes (n = 8) (B) and CD16+ monocytes (n = 7) (C), respectively, based on
the peak intensity matrix.
Figure 5 Whole-cell MALDI-TOF MS based identification of biomarkers specific for pan-monocyte and CD16+ monocytes. A) Smoothed mass
spectra quadruplicates obtained from resting pan-monocytes (n = 8, 32 red spectra) overlaid with those obtained from CD16+ monocytes
(n = 7, 28 green spectra). m/z peaks significantly over-represented in pan-monocytes (left overlay plot) or CD16+ monocytes (right overlay plot)
are indicated. B) Scatter-plot of quadruplicate’s averaged mass peak intensities from pan-monocytes and CD16+ monocytes from individual donor
are shown for the peak at 9296.1 m/z (left) and 9720.3 m/z (right). The two-way ANOVA with Bonferroni post-tests correction was used with a
significance at p < 0.001.
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the putative phosphorylated form increased specifically
under LPS stimulation of CD16+ monocytes (Figure 6C).
These two peaks were found significantly repressed in
pan-monocytes stimulated by either LPS or PPD indicating
that the respective pathway would be negatively regulated
in stimulated pan-monocytes. Accordingly, within a single
spectrum whole-cell mass spectrometry would capture
generic activation patterns as well as activation event
specific from distinct signalling pathways which remain to
be elucidated using for instance, top-down proteomic
approaches [39]. After interrogating the human protein
SwissProt database using TagIdent (formerly GuessProt)
tool and consistent with the blood origin of our biological
samples, some relevant candidates may already arise. For
instance, the pan-monocyte marker (m/z 9296.1) returned
28 hits including the chemokine CCL13. Similarly, m/z
5697 which was found significantly over-expressed in
LPS-treated CD16+ monocytes returned 14 hits of
which 3 are β − defensins and expected products of an
innate immune response upon exposure to a bacterial
component. Adequate protein identification involving
ms/ms sequencing or peptide mass fingerprints should be
performed to confirm the identity of these potential
matches. Yet, this analysis brings up that among relatively
low-molecular weights species’ candidates stands very
relevant protagonists of innate immune responses. In this
study, we have systematically performed whole-cell
MALDI-TOF on frozen cell pellets which may give rise to
criticisms on the potential impact on the freezing step on
the subsequent mass spectrometry profiles. In fact,
Ouedraogo et al. previously assessed that such freezing
procedure does not alter the monocyte fingerprint [40].
However, Munteneanu et al. demonstrated that spectrum
richness can be substantially affected by the amount of
spotted materials due to the ion suppression effect [28].
Even though, we could readily discriminate monocyte
subpopulations and activation, technical improvements
may be further achieved by addressing the optimal amount
of cells but also the nature of the matrix. Indeed, the
profiles obtained in our study using a sinapinic acid matrix
differ substantially from monocyte profiles performed with
HCCA matrix [27]. Finally, our mass spectrometry profiles
were confronted to grouping based on the current
monocyte nomenclature and the expression of CD16 and
CD14 surface markers [2]. In the future, this classification
might be refined based on the differential expression of
surface antigens such as Fc gamma receptor I (CD64)
[41], P-selectin glycoprotein ligand-1 (PSGL-1) [31],
the low-density lipoprotein receptor-related protein (LRP1)
[42] or the α2-macroglobulin receptor [43]. This would give
rise to new clusters that could be further phenotypically
discriminated by whole-cell MALDI-TOF MS profiling.
Figure 6 Whole-cell MALDI-TOF can monitor immune activation events. Vent diagrams depicting for A) Pan-monocytes or B) CD16+ monocytes,
m/z peak intensities significantly different between the detailed culture conditions (two-way ANOVA statistical analysis, p < 0.001). C) Smoothed
mass spectra quadruplicates and respective scatter-plot of quadruplicate’s averaged mass peak intensities from resting CD16+ monocytes (green
overlay) and LPS-treated CD16+ monocytes (red overlay) highlighting m/z areas containing putative phosphorylation of m/z 11316.24 into m/z
11396.28 (two-way ANOVA with Bonferroni post-tests correction, *** p < 0.001).
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Conclusions
To our knowledge, this is the first report describing the
use of quantitative whole-cell MALDI-TOF MS analysis
to identify mass spectra that discriminate resting and
activated human monocyte subsets. As a next step, we
are now aiming to identify the most relevant protein
candidates highlighted in this study. This proof of
concept could easily be translated to clinical studies
to monitor the functional status of monocytes from
patients suffering from systemic and chronic inflammatory
disorders. Diabetes mellitus has been associated with
various immune dysfunctions that could be assessed and
monitored by whole-cell mass spectrometry approaches.
The identification of disease specific markers could
provide relevant biological insights in the pathogenesis of
diabetes mellitus and the well described enhanced suscep-
tibility of patients to bacterial infection [44]. High
throughput monitoring of functional status of cell subsets
in peripheral blood based on whole cell MALDI-TOF MS
could provide unique opportunities to monitor disease
progression and resolution in clinical settings.
Additional file
Additional file 1: MALDIquant processed mass spectrometry data;
e.g. m/z peak list and their respective normalized intensities.
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